Sandoz: FDA To Review BLA For Proposed Biosimilar Denosumab
6/2 07:43
(RTTNews) - Sandoz, a Novartis (NVS) division, announced the FDA has accepted its Biologics License Application for proposed biosimilar denosumab. The BLA includes an analytical and clinical data package, including data from the Phase I/III ROSALIA study....